The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long term survival in IMAGE 1 (Immune Modulation And Gemcitabine Evaluation 1), a randomized, open-label phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer.
 
Angus George Dalgleish
Stock and Other Ownership Interests - Celgene
Honoraria - Celgene; CureVac; TNI BioTech
Consulting or Advisory Role - Bionor Pharma; Celgene; CureVac; GW Pharmaceuticals; Immodulon Therapeutics; Novartis; PRMA Consulting; Roche Pharma AG; TNI BioTech
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Celgene; GW Pharmaceuticals; Immodulon Therapeutics
Patents, Royalties, Other Intellectual Property - Celgene; GW Pharmaceuticals
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Immodulon Therapeutics; Merck Sharp & Dohme